TY - JOUR
T1 - Multi-omics reveals clinically relevant proliferative drive associated with mTOR-MYC-OXPHOS activity in chronic lymphocytic leukemia
AU - Lu, Junyan
AU - Cannizzaro, Ester
AU - Meier-Abt, Fabienne
AU - Scheinost, Sebastian
AU - Bruch, Peter Martin
AU - Giles, Holly A.R.
AU - Lütge, Almut
AU - Hüllein, Jennifer
AU - Wagner, Lena
AU - Giacopelli, Brian
AU - Nadeu, Ferran
AU - Delgado, Julio
AU - Campo, Elías
AU - Mangolini, Maurizio
AU - Ringshausen, Ingo
AU - Böttcher, Martin
AU - Mougiakakos, Dimitrios
AU - Jacobs, Andrea
AU - Bodenmiller, Bernd
AU - Dietrich, Sascha
AU - Oakes, Christopher C.
AU - Zenz, Thorsten
AU - Huber, Wolfgang
N1 - Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer Nature America, Inc.
PY - 2021/8
Y1 - 2021/8
N2 - Chronic lymphocytic leukemia (CLL) has a complex pattern of driver mutations and much of its clinical diversity remains unexplained. We devised a method for simultaneous subgroup discovery across multiple data types and applied it to genomic, transcriptomic, DNA methylation and ex vivo drug response data from 217 patients with CLL. We uncovered a biological axis of heterogeneity strongly associated with clinical behavior and orthogonal to known biomarkers. We validated its presence and clinical relevance in four independent cohorts (n = 547 patients). We found that this axis captures the proliferative drive (PD) of CLL cells, as it associates with lymphocyte doubling rate, global hypomethylation, accumulation of driver aberrations and response to pro-proliferative stimuli. CLL–PD was linked to the activation of mTOR–MYC–oxidative phosphorylation through transcriptomic, proteomic and single-cell resolution analysis. CLL–PD is a key determinant of disease outcome in CLL. Our multi-table integration approach may be applicable to other tumors whose inter-individual differences are currently unexplained.
AB - Chronic lymphocytic leukemia (CLL) has a complex pattern of driver mutations and much of its clinical diversity remains unexplained. We devised a method for simultaneous subgroup discovery across multiple data types and applied it to genomic, transcriptomic, DNA methylation and ex vivo drug response data from 217 patients with CLL. We uncovered a biological axis of heterogeneity strongly associated with clinical behavior and orthogonal to known biomarkers. We validated its presence and clinical relevance in four independent cohorts (n = 547 patients). We found that this axis captures the proliferative drive (PD) of CLL cells, as it associates with lymphocyte doubling rate, global hypomethylation, accumulation of driver aberrations and response to pro-proliferative stimuli. CLL–PD was linked to the activation of mTOR–MYC–oxidative phosphorylation through transcriptomic, proteomic and single-cell resolution analysis. CLL–PD is a key determinant of disease outcome in CLL. Our multi-table integration approach may be applicable to other tumors whose inter-individual differences are currently unexplained.
UR - https://www.scopus.com/pages/publications/85109344882
U2 - 10.1038/s43018-021-00216-6
DO - 10.1038/s43018-021-00216-6
M3 - Article
C2 - 34423310
AN - SCOPUS:85109344882
SN - 2662-1347
VL - 2
SP - 853
EP - 864
JO - Nature Cancer
JF - Nature Cancer
IS - 8
ER -